[go: up one dir, main page]

SG163584A1 - Thermoreversible immuno-adjuvant emulsion - Google Patents

Thermoreversible immuno-adjuvant emulsion

Info

Publication number
SG163584A1
SG163584A1 SG201004919-5A SG2010049195A SG163584A1 SG 163584 A1 SG163584 A1 SG 163584A1 SG 2010049195 A SG2010049195 A SG 2010049195A SG 163584 A1 SG163584 A1 SG 163584A1
Authority
SG
Singapore
Prior art keywords
oil
thermoreversible
adjuvant
immuno
emulsion
Prior art date
Application number
SG201004919-5A
Inventor
Marie-Francoise Klucker
Francois Dalencon
Patricia Probeck-Quellec
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0507240A external-priority patent/FR2888117B1/en
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of SG163584A1 publication Critical patent/SG163584A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)

Abstract

The invention relates to an oil-in-water adjuvant emulsion including at least squalene, an aqueous solvent, a nonionic surfactant which is polyoxyethylene alkyl ether and a thermoreversible hydrophobic nonionic surfactant, in which adjuvant the size of 90 % of the oil droplet volume distribution is less than 200 nm. The invention also relates to a method of preparing an immunogenic composition, wherein at least one vaccine antigen is mixed with an oil-in- water emulsion. The invention is characterised in that the oil-in- water emulsion is obtained via a temperature-variation phase inversion method.
SG201004919-5A 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion SG163584A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0507240A FR2888117B1 (en) 2005-07-07 2005-07-07 VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION
FR0508310 2005-08-04

Publications (1)

Publication Number Publication Date
SG163584A1 true SG163584A1 (en) 2010-08-30

Family

ID=37637538

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201004919-5A SG163584A1 (en) 2005-07-07 2006-07-07 Thermoreversible immuno-adjuvant emulsion

Country Status (24)

Country Link
EP (2) EP2080522B1 (en)
JP (1) JP5300475B2 (en)
KR (1) KR101328638B1 (en)
CN (1) CN101217977B (en)
AR (1) AR054822A1 (en)
AT (1) ATE424845T1 (en)
AU (1) AU2006268466B2 (en)
BR (1) BRPI0614053A2 (en)
CA (1) CA2613732C (en)
CY (2) CY1108994T1 (en)
DE (1) DE602006005671D1 (en)
DK (2) DK1904099T3 (en)
EA (1) EA012376B1 (en)
ES (2) ES2322102T3 (en)
IL (1) IL187967A0 (en)
MX (1) MX2007016412A (en)
NO (1) NO336369B1 (en)
NZ (1) NZ564173A (en)
PL (2) PL1904099T3 (en)
PT (2) PT1904099E (en)
SG (1) SG163584A1 (en)
SI (2) SI2080522T1 (en)
TN (1) TNSN08001A1 (en)
WO (1) WO2007006939A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1861120T3 (en) 2005-03-23 2016-07-25 Glaxosmithkline Biologicals Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce CD 4 T cell and / or enhanced B memory cell response
AR054822A1 (en) * 2005-07-07 2007-07-18 Sanofi Pasteur ADMISSION IMMUNE EMULSION
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
AU2011213757B2 (en) * 2005-11-04 2013-07-25 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
EP1945252B1 (en) 2005-11-04 2013-05-29 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
EP1951302A2 (en) * 2005-11-04 2008-08-06 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PL2043682T3 (en) 2006-07-17 2014-09-30 Glaxosmithkline Biologicals Sa Influenza vaccine
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
AR066405A1 (en) 2007-04-20 2009-08-19 Glaxosmithkline Biolog Sa VACCINE
MX2009012922A (en) 2007-05-31 2010-07-05 Academisch Ziekenhuis Leiden H Intradermal hpv peptide vaccination.
CN101428145B (en) * 2007-11-05 2013-01-02 北京生泰尔生物科技有限公司 Novel vaccine adjuvant
US8506966B2 (en) 2008-02-22 2013-08-13 Novartis Ag Adjuvanted influenza vaccines for pediatric use
ES2615390T3 (en) * 2008-03-05 2017-06-06 Sanofi Pasteur Process to stabilize a vaccine composition containing adjuvant
CA2733356C (en) 2008-08-01 2016-06-07 Gamma Vaccines Pty Limited Influenza vaccines
EA201500910A1 (en) 2009-02-10 2016-04-29 Новартис Аг VACCINES AGAINST FLU WITH REDUCED NUMBER OF SQUALES
CA2753497C (en) 2009-02-25 2016-07-05 Stiefel Research Australia Pty Ltd Topical foam composition
KR20120088721A (en) 2009-10-09 2012-08-08 씨바이오 리미티드 Chaperonin 10 variants
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB201009673D0 (en) * 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
JP6046632B2 (en) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ Composition for immunization against pneumococci
EP2667891B1 (en) 2011-01-27 2021-10-06 Gamma Vaccines Pty Limited Combination vaccines
EP2578974A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
KR102055176B1 (en) 2012-03-23 2019-12-12 피트니 파마슈티컬스 피티와이 리미티드 Kinase inhibitors for the treatment of cancer
KR20150021088A (en) 2012-06-05 2015-02-27 디 오스트레일리언 내셔널 유니버시티 Vaccination with interleukin-4 antagonists
WO2013184900A2 (en) 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
EP2877207A1 (en) 2012-07-24 2015-06-03 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
AU2013295014B2 (en) 2012-07-24 2018-01-18 Sanofi Pasteur Vaccine compositions
JP6441219B2 (en) 2012-08-06 2018-12-19 ピットニー・ファーマシューティカルズ・ピーティーワイ・リミテッド Compounds for treating mTOR pathway related diseases
CN103784953B (en) * 2012-10-26 2018-04-10 上海医药工业研究院 Oil-in-water type Submicron Emulsion as vaccine adjuvant and preparation method thereof
BR112015012515B1 (en) 2012-11-30 2023-04-11 Sanofi Pasteur USE OF ANTIGENS, NUCLEIC ACID CONSTRUCTS OR VIRAL VECTORS CAPABLE OF EXPRESSING A VIRUS-LIKE PARTICLE (VLP) OF DENGUE AND A VACCINE AGAINST MEASLES, A VACCINE AGAINST MUMPS AND A VACCINE AGAINST RUBELLA
CN104968358B (en) 2012-12-17 2022-11-18 新南创新有限公司 Treatment of diseases involving mucin
JP6286445B2 (en) 2012-12-24 2018-02-28 セル・アイディアズ・ピーティーワイ・リミテッド Vaccine for treatment of cancer and composition for enhancing vaccine efficacy
WO2015000014A1 (en) 2013-07-01 2015-01-08 Newsouth Innovations Pty Limited Diagnosis and treatment of autoimmune diseases
CN105288614A (en) * 2014-06-18 2016-02-03 潘皓 Vaccine composition and its preparation method
AU2015293983B2 (en) 2014-07-21 2017-02-09 Sanofi Pasteur Sa Liquid feeding device for the generation of droplets
KR20240145064A (en) 2015-03-26 2024-10-04 지피앤 백신즈 피티와이 엘티디 Streptococcal vaccine
CN105251002B (en) * 2015-11-13 2019-02-15 中国人民解放军第三军医大学 A kind of oil-in-water nanoemulsion adjuvant and MRSA nanoemulsion adjuvant vaccine and preparation method thereof
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
JP6907227B2 (en) * 2016-03-23 2021-07-21 インターベット インターナショナル ベー． フェー． Combined vaccine against PCV2 virus and Mycoplasma hyopinium infection
KR102037041B1 (en) * 2016-08-10 2019-10-29 (주)셀트리온 Stable Liquid Pharmaceutical Formulation of Anti-Influenza Virus Antibody
PL3601367T3 (en) 2017-03-30 2025-03-31 The University Of Queensland Chimeric molecules and uses thereof
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
EP4199962A1 (en) 2020-08-24 2023-06-28 Sanofi Pasteur Inc. Vaccines against sars-cov-2 infections
TW202502375A (en) 2023-03-02 2025-01-16 法商賽諾菲公司 Compositions for use in treatment of chlamydia
CN118662475A (en) * 2023-03-16 2024-09-20 清华大学 Preparation and application of solidified self-microemulsified vaccine
TW202500750A (en) 2023-05-05 2025-01-01 法商賽諾菲公司 Compositions for use in treatment of acne

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
DE68929478T2 (en) 1988-01-29 2004-04-29 Aventis Pasteur Recombinant CMV neutralization proteins
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
FR2723740B1 (en) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc PROCESS FOR THE PREPARATION OF INFLUENZA VIRUS ANTIGENS, ANTIGENS OBTAINED AND THEIR APPLICATIONS
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
FR2773156B1 (en) 1997-12-26 2000-03-31 Biovacs Inc NOVEL ANTI-RETROVIRAL IMMUNOGENS (TOXOIDS), NOVEL PREPARATION METHODS AND APPLICATION TO AIDS PREVENTION AND TREATMENT
US6299848B1 (en) * 1998-09-25 2001-10-09 Hamon Research-Cottrell Process for removing sulfur dioxide out of a gas
TR200103018T2 (en) * 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline Additive compounds containing immunostimulatory oligonucleotide and saponin.
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
WO2002076392A2 (en) * 2001-03-21 2002-10-03 Madash Llc Thermally reversible water in oil in water emulsions
AR054822A1 (en) * 2005-07-07 2007-07-18 Sanofi Pasteur ADMISSION IMMUNE EMULSION

Also Published As

Publication number Publication date
PT2080522E (en) 2012-10-01
WO2007006939A2 (en) 2007-01-18
KR20080030076A (en) 2008-04-03
CA2613732A1 (en) 2007-01-18
ATE424845T1 (en) 2009-03-15
IL187967A0 (en) 2008-03-20
JP5300475B2 (en) 2013-09-25
EP2080522B1 (en) 2012-07-04
AR054822A1 (en) 2007-07-18
AU2006268466B2 (en) 2011-11-10
ES2322102T3 (en) 2009-06-16
WO2007006939A3 (en) 2007-04-05
EA012376B1 (en) 2009-10-30
NZ564173A (en) 2010-10-29
CY1113414T1 (en) 2016-06-22
SI1904099T1 (en) 2009-08-31
EA200800271A1 (en) 2008-04-28
PL2080522T3 (en) 2012-11-30
EP2080522A1 (en) 2009-07-22
PT1904099E (en) 2009-05-29
KR101328638B1 (en) 2013-11-27
EP1904099A2 (en) 2008-04-02
JP2009500382A (en) 2009-01-08
MX2007016412A (en) 2008-03-07
EP1904099B1 (en) 2009-03-11
AU2006268466A1 (en) 2007-01-18
NO336369B1 (en) 2015-08-10
SI2080522T1 (en) 2012-10-30
TNSN08001A1 (en) 2009-07-14
DE602006005671D1 (en) 2009-04-23
CN101217977B (en) 2013-03-06
DK2080522T3 (en) 2012-10-08
DK1904099T3 (en) 2009-06-08
ES2390104T3 (en) 2012-11-06
CY1108994T1 (en) 2014-07-02
BRPI0614053A2 (en) 2011-03-09
CN101217977A (en) 2008-07-09
PL1904099T3 (en) 2009-08-31
NO20080585L (en) 2008-03-26
CA2613732C (en) 2013-12-10

Similar Documents

Publication Publication Date Title
SG163584A1 (en) Thermoreversible immuno-adjuvant emulsion
TW200716165A (en) Novel vaccine formulations
BRPI0000126B8 (en) vaccine composition, adjuvant composition and method of producing a vaccine composition
HRP20080235T3 (en) FORMULATION OF VACCINE CONTAINING OIL-IN-WATER EMULSION
EA200901161A1 (en) VACCINE AGAINST THE FLU IN THE FORM OF THE TYPE "OIL IN WATER" EMULSION
NZ594482A (en) Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant
WO2007098186A3 (en) Adjuvant and vaccine compositions
EP2340710A3 (en) Stable emulsion formulation hindering interaction across the water-oil interface
EP2319484A3 (en) Water-in-oil emulsion system and preparation process thereof
NZ568210A (en) Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
DE60020677D1 (en) MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND MICROPARTICLES
JP2009500382A5 (en)
HRP20140488T1 (en) Influenza vaccine
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
WO2008039564A8 (en) Process for solubilization of flavor oils
CL2008001383A1 (en) Aerated and lyophilized dairy or milk replacer composition comprising a dairy ingredient or milk replacer, an emulsifier, a viscosity improver; and method of preparing said composition.
PT2164510E (en) Emulsion vaccine compositions comprising antigen and adjuvant in the aqueous phase
WO2001089474A3 (en) O/w emulsion
WO2010092479A3 (en) Influenza vaccines with reduced amounts of squalene
RU2017101091A (en) COMPOSITIONS OF DOUBLE ADJUVANT VACCINES, OBTAINING AND APPLICATIONS
GB2534038A (en) Oil-in-water stable, emulsified spacer fluids
RU2007106055A (en) AN ANTIPERSPIENT OR DEODORANT EMULSION CONTAINING A NON-IONOGENIC EMULSANT AND COLLOID SILICON DIOXIDE
WO2009053601A3 (en) Method for preparing a vaccine composition comprising at least one antigen and at least one adjuvant
EA201001478A1 (en) VACCINE
AU5851701A (en) Method for preparing a monodispersed double emulsion